You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.


Go back

*The primary endpoint was the proportion of ACT responders (improvement from baseline of ≥3 or achieving a total ACT of ≥20) in patients initiating Relvar vs. continuing usual care (as prescribed by GP) at months 6 in the PEA (primary effectiveness analysis) population. The primary endpoint was met (p<0.001). Data presented are from a subset of patients in the PEA population prescribed ICS/LABA at baseline: 70% of patients initiating with Relvar (n=637/908) improved asthma control vs. 56% of patients continuing on their ICS/LABA (n=511/916). OR 1.95, 95% CI: 1.60, 2.38. 225% relative improvement, 14% actual improvement - use the language normally use from core claims.

**95% of patients use Ellipta correctly after one demonstration. 6


  1. Relvar Ellipta SmPC, available on 2018.
  2. Woodcock A et al. Lancet 2017; 390:2247–2255.
  3. Braithwaite I et al. Respir Med 2016; 119:115–121.
  4. Bardsley G et al. Respir Res 2018; 19:133.
  5. van der Palen J et al. Prim Care Respir Med 2016; 26:16079.
  6. Svedsater H et al. Prim Care Respir Med 2014; 24:14019.
  7. GSK DoF RF/FFT/0101/17.

RELVAR Ellipta was developed in collaboration with INNOVIVA Inc.

Adverse events should be reported to the Health Products Regulatory Authority (HPRA) using an Adverse Reaction Report Form obtained either from the HPRA or electronically via the website at Adverse events can also be reported to the HPRA by calling: (01) 6764971. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.